New resource available view now
New resource available view now
Recent Post
Related Posts
IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025
Strategic Pivot to Pure-Play Biotech
IGC Pharma to Showcase AI Platform with Alzheimer’s Disease Data Initiative at ADPD 2026
POTOMAC, Maryland – March 18, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics for Alzheimer’s disease, today announced it will demonstrate its Agentic Harmonization Assistant
Healing from within: Gut Health Strategies That May Slow Alzheimer’s progression
Scientific breakthroughs have the potential to transform our understanding of disease and open new avenues for treatment. In Alzheimer’s research, one of the most recent and unexpected advances has
POTOMAC, MARYLAND – February 26, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics for Alzheimer’s disease, today announced the filing
IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets
POTOMAC, MARYLAND – February 24, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that Ascendiant Capital Markets has issued an updated equity research report